Radius Health, Inc.

Radius Health — JP Morgan Healthcare Conference 2020

32 slides from Radius Health's conference presentation, Jan 13, 2020

  1. Slide 1: JP Morgan Healthcare Conference

    Slide 1: JP Morgan Healthcare Conference

    JP Morgan healthcare conference JESPER HOEILAND, CEO JANUARY 14, 2020 Exhibit 99.2

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    Safe Harbor Any statements made in this presentation relating to future financial or business performance, guidance, conditions, plans, prospects, trends or strategies and other financial or business matters, including regarding the commercialization of TYMLOS® (abaloparatide) injection in the U.S.,

  3. Slide 3: Strategy for growth and continued leadership

    Slide 3: Strategy for growth and continued leadership

    ENDOCRINE DISEASES Abaloparatide-PATCH TYMLOS Grow Portfolio through Selective Strategic Assets Targeted Endocrine Diseases Selective Investments to Complement Sales Offering Partner of Choice in the U.S. Expand Market Opportunity Increase Anabolic Use for OP1 via Novel Route of Administration Grow

  4. Slide 4: 2019 achievements

    Slide 4: 2019 achievements

    2019 achievements 1 Access to non-dilutive financing up to $75m (+$20m accordion); 2 Cash, cash equivalents and marketable securities Exceeded Full-Year TYMLOS U.S. Net Sales Guidance Reaching > $172M Revenues TYMLOS Took Leadership in New PMO Patient Starts (NBRx) with Anabolics in Q4 2019 Expanded

  5. Slide 5: Radius runway for growth

    Slide 5: Radius runway for growth

    Radius RUNWAY FOR GROWTH 1 NBRx: New Patient To Brand Drug; 2 Signed in January 2020 3 Until 1H 2023 2017 2018 2019 ACHIEVED 2020 + 2 YEARS3 3-YEAR OUTLOOK TYMLOS $220-235m Net Sales Market Leadership Complete Recruitment in 3 Phase 3’s wearable EMERALD ATOM (Male OP) Elacestrant out-licensing to ma

  6. Slide 6: Pipeline Review

    Slide 6: Pipeline Review

    Pipeline Review

  7. Slide 7: Radius clinical pipeline with three Phase 3 studies

    Slide 7: Radius clinical pipeline with three Phase 3 studies

    Radius CLINICAL PIPELINE WITH THREE Phase 3 studies PRECLINICAL PHASE 1 PHASE 2 PHASE 3 EXPECTED DATA Abaloparatide-SC Osteoporosis Anabolic Subcutaneous Injection In Market Abaloparatide-SC Osteoporosis Anabolic Subcutaneous Injection 2H 2021 Abaloparatide-Patch Osteoporosis Anabolic Transdermal Pa

  8. Slide 8: Osteoporosis is a Large and Underserved Market

    Slide 8: Osteoporosis is a Large and Underserved Market

    Osteoporosis is a Large and Underserved Market 5.2M Patients 2.7M Patients 50k Patients US Prevalence of Women 50 yrs+ Diagnosed with Osteoporosis* Treated with Osteoporosis drugs** Treated with Anabolic Drugs** 1.8M high-risk 0.9M w/ fracture < 5% Penetration ~50% Diagnosis Rate Under-treatment of

  9. Slide 9: TYMLOS Fracture Risk Reduction Efficacy from ACTIVE Phase 3

    Slide 9: TYMLOS Fracture Risk Reduction Efficacy from ACTIVE Phase 3

    TYMLOS Fracture Risk Reduction Efficacy from ACTIVE Phase 3 Time to Event for Nonvertebral Fractures Select Osteoporosis (OP) Therapies Reduction in Fractures from Various Placebo-Controlled Studies * USPI and ACTIVE Study; **USPI and FREEDOM Study; ***USPI and FIT1 Study, ****FRAME study, RRR in no

  10. Slide 10: Potential to Transform Anabolic Use for Osteoporosis

    Slide 10: Potential to Transform Anabolic Use for Osteoporosis

    Potential TO Transform Anabolic Use for oSTEOPOROSIS Anabolic Market Research Top Reasons to Not Prescribe Out of pocket, coverage Needle averse patients Needle phobic patients Expected compliance Novel route of administration expected* to increase use of anabolics for osteoporosis and result in hig

  11. Slide 11: PINP Levels: Abaloparatide-Patch Patient Assessment Study

    Slide 11: PINP Levels: Abaloparatide-Patch Patient Assessment Study

    PINP Levels: Abaloparatide-Patch Patient Assessment Study abaloparatide patch: established Proof of concept Study-022 Abalo patch 300 µg Day 29 N = 22 ACIVE Abalo SC 80 µg Month 1 N = 187 Baseline (ng/mL) 57.0 54.2 Mean (SD) (22.2) (20.5) Value at Day 29 (ng/mL) 109.5 110.6 Mean (SD) (54.7) (64.2) A

  12. Slide 12: Abaloparatide-patch wearABLe Phase 3 study

    Slide 12: Abaloparatide-patch wearABLe Phase 3 study

    abaloparatide-patch WEARABLE PHASE 3 STUDY SPA agreement with FDA Over 60 sites open for enrollment in the US, additional sites being opened in the US 85% of activated sites are screening patients Screen failure rate improving driven by higher screening success at bone power sites with link to Fract

  13. Slide 13: TYMLOS male osteoporosis Phase 3 ATOM study

    Slide 13: TYMLOS male osteoporosis Phase 3 ATOM study

    TYMLOS male osteoporosis phase 3 atom STUDY 1 week 1 month 12 months Pre-treatment Period Follow-up Period Treatment Period Abaloparatide-SC 80µg (n=150) Abaloparatide-SC Placebo (n=75) Randomization Ph 3 bridging study to assess efficacy and safety of abaloparatide in men Randomized, double-blind,

  14. Slide 14: Elacestrant EMERALD Phase 3 study

    Slide 14: Elacestrant EMERALD Phase 3 study

    Elacestrant EMERALD Phase 3 STUDY Phase 1 data from heavily treated patients: 19.4% ORR, 33% ORR in ESR-1 mutants and 4.5m mPFS EMERALD only Phase 3 study for oral SERD monotherapy Enrollment on pace for recruitment completion of 466 patients by Q3 2020 Elacestrant (RAD1901) 400 mg PO QD Investigato

  15. Slide 15: Commercial Update

    Slide 15: Commercial Update

    Commercial Update Joe Kelly SVP SALES, MARKETING & operations

  16. Slide 16: Abalo-Patch Leadership in an Anabolic Market

    Slide 16: Abalo-Patch Leadership in an Anabolic Market

    2019-2021 Disruption Expansion Differentiation Abalo-Patch Leadership in a 3X Anabolic Market Patch Study Results Expand Market by Leveraging HCP & Patient Demand Enhance Utilization Management given Novel Route of Administration Earlier & Expanded Use Phase 3 ACTIVExtend Increase Usage with Sequent

  17. Slide 17: Differentiation of TYMLOS for top prescribers

    Slide 17: Differentiation of TYMLOS for top prescribers

    Verbatim Observations TYMLOS “…reduces fracture risk...” “…the effects on bone seem to occur faster” “That the med may be stored without refrigeration that it is easy to inject ” “Patients welcome the idea of shorter duration of a daily self injected therapy” “Stimulates bone formation” “…better on

  18. Slide 18: Further expanded TYMLOS Market Access for 2020

    Slide 18: Further expanded TYMLOS Market Access for 2020

    FURTHER expanded TYMLOS Market Access for 2020 Covered Lives Source: MMIT as of 1/9/2020; Payor Mix Source: IQVIA Xponent Data as of December 20, 2019 Effective 1/1/2020, TYMLOS has been added to the Aetna and CIGNA MPD formularies. Effective 1/1/2020, TYMLOS WAC Price increased by 7.9%. Expected Ne

  19. Slide 19: TYMLOS On-Track for Anabolic Market Leadership in 2020

    Slide 19: TYMLOS On-Track for Anabolic Market Leadership in 2020

    TYMLOS On-Track for Anabolic Market Leadership(TRx) in 2020 Annual Share (NBRx & Total Rx*) Source: IQVIA NPA Monthly and New to Brand Monthly, Jun 2017 through Dec 2018; IQVIA NPA Weekly, week ending 1/4/2019 through week ending 12/27/2019 Anabolic Market drugs include TYMLOS and Forteo and exclude

  20. Slide 20: Preparing for Patch Launch by expanding prescriber base

    Slide 20: Preparing for Patch Launch by expanding prescriber base

    18% of NRx volume & 37% of writers are new-to-anabolics; 45% of new-to-anabolic writers are PCPs Preparing FOR Patch Launch by expanding prescriber base 45% of New To Anabolic writers are PCPs 44% of New To Anabolic volume is from PCPs Source: IQVIA Xponent Jul 2018 – Sep 2019 New To Anabolic = no a

  21. Slide 21: Financial Review

    Slide 21: Financial Review

    Financial Review Pepe Carmona CHIEF financial OFFICER

  22. Slide 22: TYMLOS sales growth drives value creation

    Slide 22: TYMLOS sales growth drives value creation

    Tymlos sales growth drives value creation $12 $99 > $172* TYMLOS U.S. Net Revenue USD in millions TYMLOS sales cover SG&A and partially fund clinical pipeline Optimized cash burn through financial discipline Non-dilutive funding access supports patch pre-launch and robust minimum cash End Year Cash

  23. Slide 23: Cash Burn

    Slide 23: Cash Burn

    All numbers in USD million, non-US GAAP Cash Burn TYMLOS Covering SG&A and partially Funding Clinical Pipeline

  24. Slide 24: Financial Guidance

    Slide 24: Financial Guidance

    FINANCIAL GUIDANCE 1 Access to non-dilutive financing up to $75m (+$20m accordion) supports expansion of business with abaloparatide-patch launch and other endocrine areas. Potential proceeds from oncology assets strategic transaction expected to also support expanding product portfolio and clinical

  25. Slide 25: Closing Remarks

    Slide 25: Closing Remarks

    Closing Remarks Jesper

  26. Slide 26: 2020 Milestones

    Slide 26: 2020 Milestones

    2020 Milestones 1 Post-menopausal Osteoporosis: 2 Metastatic breast cancer Grow Full-Year TYMLOS U.S. Net Sales to between $220m to $235m Reach Anabolic Market Leadership (TRx) for TYMLOS in 2H 2020 Complete Recruitment in TYMLOS Male Osteoporosis Phase 3 Study Complete Recruitment in wearABLe Abalo

  27. Slide 27: Q&A

    Slide 27: Q&A

    Q&A

  28. Slide 28: Appendix

    Slide 28: Appendix

    Appendix

  29. Slide 29: Q1 2020 Market Seasonality

    Slide 29: Q1 2020 Market Seasonality

    Q4 2019 Q1 2020 Market Seasonality Market Share Price Seasonality All numbers in USD million 54+ (4) – (3) 3 – 6 (10) – (9) 45 - 48 * Higher patient abandonment rate early in the year ** Phasing of patients entering Medicare Part D Coverage Gap (70% manufacturer contribution) and support for commerc

  30. Slide 30: Non-dilutive financing details

    Slide 30: Non-dilutive financing details

    Tranche 1 $10M at closing Tranche 2 $15M no later than 3/31/20 Tranche 3* $15m no later than 12/31/21 Tranche 4* $15M no later than 12/31/21 Interest Rate of LIBOR + 5.75% (LIBOR floor of 2%) Non-dilutive financing DETAILS Access up to $95M Non-Dilutive Financing (maturity Date of June 1, 2024) $55M

  31. Slide 31: Reconciliation Non-GAAP to US GAAP 2018

    Slide 31: Reconciliation Non-GAAP to US GAAP 2018

    Reconciliation Non-GAAP to US GAAP ($M) Q1 2018 Q2 2018 Q3 2018 Q4 2018 GAAP Net Loss (61.6) (68.9) (49.8) (41.1) Stock-based compensation: Research and Development 3.2 3.7 2.4 2.4 Stock-based compensation: Selling, General and Administrative 4.3 4.3 4.3 4.1 Intangible asset amortization 0.2 0.2 0.2

  32. Slide 32: Reconciliation Non-GAAP to US GAAP 2019

    Slide 32: Reconciliation Non-GAAP to US GAAP 2019

    Reconciliation Non-GAAP to US GAAP ($M) Q1 2019 Q2 2019 Q3 2019 GAAP Net Loss (42.8) (35.5) (30.0) Stock-based compensation: Research and Development 2.1 2.0 1.6 Stock-based compensation: Selling, General and Administrative 4.0 3.8 3.4 Intangible asset amortization 0.2 0.2 0.2 Restructuring charges:

Source: SEC EDGAR · 8-K filed Jan 13, 2020

More decks from Radius Health, Inc.